The following is a summary of data from the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which is being held through Thursday in Chicago.

• Basilea Pharmaceutica Ltd., of Basel, Switzerland, said its antibiotic BAL30376 demonstrated broad-spectrum in vitro activity targeting multi-resistant Gram-negative bacteria. Data showed that the minimal inhibitory concentrations of the drug for many strains of beta-lactam-resistant bacteria were lower than those of comparator antibiotics, and the in vitro antimicrobial spectrum of BAL30376 included strains of Acinetobacter, Pseudomonas aeruginosa and Klebsiella pneumonia that were not susceptible to any of the other antibiotics tested.

• BioAlliance Pharma SA, of Paris, said in vitro data showed that repeated exposure to miconazole, an antifungal agent, does not induce fungal resistance. Results demonstrated that Fluconazole-resistant strains of Candida were and remained sensitive to miconazole despite repeated administrations. BioAlliance is in Phase III development in the U.S. for its version of miconazole formulated using its Lauriad technology as a once-daily muco-adhesive buccal tablet. It previously gained commercial approval in France for oral candidiasis in immune-compromised patients.

• Idera Pharmaceuticals Inc., of Cambridge, Mass., said preclinical data on IMO-2125, its Toll-like receptor 9 agonist for hepatitis C virus infection, showed the drug induced dose-dependent induction of interferon-alpha and other cytokines and chemokines in human immune cell cultures in vitro and in nonhuman primates in vivo. In addition, supernatants from cell cultures and plasma from non-human primates treated with IMO-2125 demonstrated antiviral activity in the HCV replicon assay, an in vitro system to measure the potency of antiviral compounds against HCV replication.

• Replidyne Inc., of Louisville, Colo., said preclinical findings from its REP3123 C. difficile program showed the compound is able to inhibit growth, halt toxin production and prevent spore-formation of the Gram-positive bacterium, without inhibiting other key organisms essential for normal intestinal functioning.